Finance members request actuarial review of biomarker bill amid insurance-cost concerns

Members of the Finance committee asked the Department of Financial Regulation (DFR) to prepare an actuarial assessment of a proposed biomarker bill that committee members said could influence health-insurance costs.

The committee discussed testimony from Health & Welfare that the measure includes fees and that, under Rule 31, revenue impacts outside the committee’s jurisdiction must be identified. A member said the state could be responsible for the full cost if the bill advances to the floor; the chair indicated she would present the bill for committee consideration.

Committee participants reported widely varying cost estimates for individual biomarker tests, with figures mentioned in the discussion ranging from roughly $46 to $2,500 depending on the marker and context. Members noted that many clinical pathways require multiple markers and that identifying effective, targeted biomarkers could reduce downstream costs by avoiding ineffective treatments such as trial-and-error chemotherapy.

Officials flagged practical and fiscal questions that remain unresolved: how many and which biomarkers the bill would cover; whether insurers would be required to cover multiple tests; and how the state or insurers would absorb the cost. Staff said Health & Welfare asked DFR to model these scenarios so the committee can better understand the budgetary consequences.

The chair said the measure is being moved forward procedurally so an estimate can be produced, but that the bill as currently drafted would not necessarily return to the committee before it hits the floor. Committee members said further revisions and fixes are expected next week after the actuarial assessment is completed.

Next steps: DFR will provide an actuarial estimate; members and staff said they expect technical fixes and clarifications to be circulated before the bill proceeds.